Infections Associated With the Use of Alemtuzumab

May 22, 2012 updated by: Won Seog Kim, Samsung Medical Center

Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab

The aim of this study is to propose infection prophylaxis from Asian multinational retrospective analysis of infectious complications in patients who were treated with alemtuzumab

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

182

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Hong Kong, China
        • Queen Mary Hospital
  • Indonesia
      • Jakarta, Indonesia
        • Cipto mangunkusumo general hospital
  • Korea, Republic of
      • Seoul, Korea, Republic of
        • Samsung Medical Center
  • Taiwan
      • Teipei, Taiwan
        • National Taiwan University Hospital
  • Thailand
      • Bangkok, Thailand
        • Chulalongkorn University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 90 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients received alemtuzumab as a treatment for hematologic malignancy

Description

Inclusion Criteria:

  • Patients received alemtuzumab as a treatment for hematologic malignancy ex. non-Hodgkin lymphoma Acute myeloid leukemia Aplastic anemia

Exclusion Criteria:

  • Patients did not receive alemtuzumab

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Alemtuzumab
Patients treated with alemtuzumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Infectious event
Time Frame: one year
Any infectious complication occurred within one year after the use of alemtuzumab
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Collaborators

National Taiwan University Hospital
Chulalongkorn University
Asan Medical Center
Yonsei University
Kyungpook National University Hospital
Queen Mary Hospital, Hong Kong
Soon Chun Hyang University
Dr Cipto Mangunkusumo General Hospital
Chonnam National University
Chonbuk National University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (Actual)

March 1, 2012

Study Completion (Actual)

March 1, 2012

Study Registration Dates

First Submitted

March 13, 2011

First Submitted That Met QC Criteria

March 13, 2011

First Posted (Estimate)

March 15, 2011

Study Record Updates

Last Update Posted (Estimate)

May 24, 2012

Last Update Submitted That Met QC Criteria

May 22, 2012

Last Verified

May 1, 2012

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2009-03-006

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patients Treated With Alemtuzumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe